PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Early In-Hospital ARNI After MI: Promising but PARADISE-MI Anchors Caution

sacubitril/valsartanARNIACE inhibitorARBacute myocardial infarctionLV dysfunctionheart failureventricular arrhythmiaNT-proBNPmeta-analysissecondary preventionPARADISE-MI Cardiology

Background Information

Early ARNI therapy post-AMI cuts cardiovascular events by 42%.

Heart failure is a common complication after acute myocardial infarction (AMI) in patients with impaired left ventricular ejection fraction (LVEF). Early angiotensin-receptor-neprilysin inhibitor (ARNI) initiation reduced major adverse cardiovascular events (MACEs) by 42% and improved LVEF by 2.54%, but increased symptomatic hypotension risk. ARNI therapy shows promise for early post-AMI management, but the increased risk of hypotension requires careful monitoring. Early ARNI initiation post-AMI reduces MACEs and improves LVEF but watch for hypotension.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Nguyen Q, Tran TTQ, Liao CT, Hung CL, Chang HY, Chen CW, Lin YC, Huang CY, Hsu CY

Citation: Nguyen Q, Tran TTQ, Liao CT, et al. Early in-hospital initiation of angiotensin-receptor-neprilysin inhibitor in post-acute myocardial infarction patients with impaired left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. Frontiers in cardiovascular medicine. 2026;13:1877075. doi:10.3389/fcvm.2026.1877075

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.